Whole Genome Sequencing of cell-free-DNA in High-Risk Smoldering Multiple Myeloma

In this study, we used 40x whole-genome sequencing of plasma cfDNA from high risk smoldering multiple myeloma patients (HR-SMM) to assess minimal residual disease (MRD) status. We generated 87 BAM files from patients at baseline, at progression or MRD conversion, and 3- and 6- months before progression or MRD conversion.

• Type: Whole Genome Sequencing
• Archive: European Genome-phenome Archive (EGA)